

**Multidisciplinary Care of Pediatric and Adolescent Patients
with Moderate to Severe Atopic Dermatitis**

TOOL KIT

| | |
|---|---|
| Silverberg JI. Comorbidities and impact of atopic dermatitis. <i>Ann Allergy Asthma Immunol.</i> 2019;123:144-151. | https://pubmed.ncbi.nlm.nih.gov/31034875/ |
| Simpson EL, et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. <i>J Am Acad Dermatol.</i> 2016;74:491-498. | https://pubmed.ncbi.nlm.nih.gov/26777100/ |
| Wang D, Beck LA. Immunologic targets in atopic dermatitis and emerging therapies: An update. <i>Am J Clin Dermatol.</i> 2016;17:425-443. | https://pubmed.ncbi.nlm.nih.gov/27371134/ |
| Gandhi NA, et al. Targeting key proximal drivers of type 2 inflammation in disease. <i>Nat Rev Drug Discov.</i> 2016;15:35-50. | https://pubmed.ncbi.nlm.nih.gov/26471366/ |
| Eichenfield LF, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. <i>J Am Acad Dermatol.</i> 2014;70:338-351. | https://pubmed.ncbi.nlm.nih.gov/24290431/ |
| Saeki H, et al. Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. <i>J Dermatol.</i> 2016;43:1117-1145. | https://pubmed.ncbi.nlm.nih.gov/27076388/ |
| Wollenberg, A, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. <i>J Eur Acad Dermatol Venereol.</i> 2018;32:657-682. | https://pubmed.ncbi.nlm.nih.gov/29676534/ |
| Shi VY, et al. Improving patient education with an eczema action plan: a randomized controlled trial. <i>JAMA Dermatol.</i> 2013;149:481-483. | https://pubmed.ncbi.nlm.nih.gov/23553035/ |
| Paller AS, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. <i>J Am Acad Dermatol.</i> 2016; 75:494-503. | https://pubmed.ncbi.nlm.nih.gov/27417017/ |
| Schlessinger J, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: A phase IV open-label study (CrisADe CARE 1). <i>Am J Clin Dermatol.</i> 2020;21:275-284. | https://pubmed.ncbi.nlm.nih.gov/32212104/ |

| | |
|--|--|
| <p>Simpson EL, et al. Efficacy and Safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: A phase 3 randomized clinical trial. <i>JAMA Dermatol.</i> 2020;156:44-56.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/31693077/</p> |
| <p>Paller AS, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial. <i>J Am Acad Dermatol.</i> 2020;Jun 20: Epub ahead of print.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/32574587/</p> |
| <p>Simpson EL, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. <i>N Engl J Med.</i> 2016;375:2335-2348.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/27690741/</p> |
| <p>Blauvelt A, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet.</i> 2017;389:2287-2303.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/28478972/</p> |
| <p>De Bruin-Weller M, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance in ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). <i>Br J Dermatol.</i> 2018;178:1083-1101.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/29193016/</p> |
| <p>Deleuran M, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>J Am Acad Dermatol.</i> 2020;82:377-388.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/31374300/</p> |
| <p>Guttman-Yassky E, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: A phase 2b randomized clinical trial. <i>JAMA Dermatol.</i> 2020;156:411-420.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/32101256/</p> |
| <p>Wollenberg A, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. <i>J Allergy Clin Immunol.</i> 2019;143:135-141.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/29906525/</p> |
| <p>Silverberg, JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. <i>J Allergy Clin Immunol.</i> 202;145:173-182.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/31449914/</p> |
| <p>Guttman-Yassky E, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>J Allergy Clin Immunol.</i> 2020;145:877-884.</p> | <p>https://pubmed.ncbi.nlm.nih.gov/31786154/</p> |

Guttman-Yassky E, et al. **Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.** *J Am Acad Dermatol.* 2019;80:913-921.e9.

<https://pubmed.ncbi.nlm.nih.gov/29410014/>

Silverberg JI, et al. **Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial.** *JAMA Dermatol.* 2020;e201406.

<https://pubmed.ncbi.nlm.nih.gov/32492087/>